ClinicalTrials.gg
RecruitingNCT07353710SONAR-ICEUpdated Oct 22, 2026

A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure

An interventional study of ICE Image Acquisition in Atrial Arrhythmia and Intracardiac Echocardiography, sponsored by Boston Scientific Corporation. Recruiting at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 22, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A first-in-human prospective data collection study including subjects who are planned to undergo an ablation procedure for any atrial arrhythmia as per medical judgement and the site's standard practice, represents the most viable means to collect human anatomy ICE images for the purpose of software development.

02

Conditions studied

  • Atrial Arrhythmia
  • Intracardiac Echocardiography
03

In context

Lead sponsor

Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able and willing to provide written prior to any study procedure.
  2. Subjects who are planned for an ablation procedure for any atrial arrhythmia using any commercially available Boston Scientific Ablation System, per physician's judgement and hospitals' standard practice.
  3. Subjects who are willing and able to participate in all testing and assessments associated with this clinical study at an approved clinical investigation center.
  4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following cardiac implanted devices

    • Any prosthetic mitral or tricuspid heart valve, such as ring, repairs or clips
    • Atrial septal defect (ASD) occluders including interatrial baffle, closure device, patch, or patent foramen ovale or ASD occluder
  2. Subjects with related to the use of the CHORUS IDx™ System:

    • Subjects with inadequate vascular access
    • Subjects with active systemic infection
    • Subjects with presence of a known intracardiac thrombus in the chamber of use
  3. Women who are confirmed to be pregnant or lactating at the time of the Index Procedure
  4. Presence of other medical conditions, that, in the investigator's opinion, could limit the subject's ability to participate in the study
  5. Subjects who are currently enrolled in another study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Treatment

    Subjects with at least one ICE image collected with the investigational system

    Device: ICE Image Acquisition

Interventions

  • DeviceICE Image Acquisition

    ICE image acquisition using the investigational device

06

What researchers measure

Primary outcomes

  1. The incidence of procedure related serious adverse events and all adverse events

    Incidence of safety events that have occurred in subjects in whom the investigational device has been inserted, including: * Index Procedure related serious adverse events up to day 7 after the Index Procedure * All adverse events Note: Imaging data will be used for development and validation of the software.

    Time frame: 7 Days

07

Study locations

4 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Jan 20, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Lingard Private Hospital · Merewether, AustraliaNot yet recruiting→Recruiting
  • IKEM - Institut klinicke a experimentalni mediciny · Prague, CzechiaNot yet recruiting→Recruiting
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Lingard Private Hospital · Merewether, AustraliaNot yet recruiting→Recruiting
    • IKEM - Institut klinicke a experimentalni mediciny · Prague, CzechiaNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07353710
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jul 28, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Nele Cielen
Contact
nele.cielen@bsci.com
0470991143 ext. 0032

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion